Effect of a Cytoprotective Dose of Dehydroleucodine, Xanthatin, and 3-Benzyloxymethyl-5H-furan-2-one on Gastric Mucosal Lesions Induced by Mast Cell Activation

Abstract

The aim of this study was to determine whether the lactones dehydroleucodine, xanthatin and 3-benzyloxymethyl-5H-furan-2-one, would be effective in an animal model of gastric ulcer induced by mast cell activation. Rats were divided into ten groups. Treatments were repeated for four days. The degree of gastric erosion was assessed with a scoring system and histological preparations. Gastric mast cell morphology was analyzed by histological procedures. Serum serotonin levels were determined as markers of mast cell activation. Statistical analyses were done using ANOVA and Tukey–Kramer test. We demonstrated that the repeated administration of compound 48/80 results in extensive mucosal lesions in the gastric mucosa and that such lesions occurred in association with mast cell degranulation and a significant increase of serum serotonin. We showed that these lesions were prevented by dehydroleucodine, xanthatin, and 3-benzyloxymethyl-5H-furan-2-one and that this effect was similar to that obtained with sodium cromoglycate. In conclusion, the results of the present study indicate that the optimal gastric cytoprotective dose of dehydroleucodine, xanthatin, and 3-benzyloxymethyl-5H-furan-2-one is efficacious in an animal model of gastric ulcer induced by mast cell activation. Our findings suggest that these lactones could be valuable tools for designing novel therapeutic agents for digestive disorders associated with inappropriate mast cell activation.

Oral supramolecular nanovectors for dual natural medicine codelivery to prevent gastric mucosal lesion

“…Gastric mucosal lesions (GMLs) usually cause gastric erosion, hemorrhage, and ulcer. 1 Over 10% of the population worldwide suffers from GML. Patients often experience very long symptom durations and are easy to relapse.…”

Mast Cells: When the Best Defense Is an Attack?

“…In this Special Issue, Bilotta et al [ 5 ] point to resveratrol, a natural inhibitor of human intestinal MC activation, as an anti-inflammatory nutraceutical in the treatment of MC-associated diseases. Moreover, Vera et al [ 6 ] highlight lactones (dehydroleucodine, xanthatin, and 3-benzyloxymethyl-5H-furan-2-one) as valuable tools for designing novel therapeutic agents for digestive disorders since they show a cytoprotective effect on gastric mucosal lesions induced by inappropriate MC activation.…”